Drug Delivery System pp 147-157

Part of the Methods in Molecular Biology book series (MIMB, volume 1141)

Antibody Labeling with Radioiodine and Radiometals

  • Suprit Gupta
  • Surinder Batra
  • Maneesh Jain
Protocol

Abstract

Antibodies have been conjugated to radionuclides for various in vitro and in vivo applications. Radiolabeled antibodies have been used in clinics and research for diagnostic applications both in vitro as reagents in bioassays and in vivo as imaging agents. Further, radiolabeled antibodies are used as direct therapeutic agents for cancer radioimmunotherapy or as tracers for studying the pharmacokinetics and biodistribution of therapeutic antibodies. Antibodies are labeled with radiohalogens or radiometals, and the choice of candidate radionuclides for a given application is dictated by their emission range and half-life. The conjugation chemistry for the coupling of MAbs with the radiometals requires a chelator, whereas radiohalogens can be incorporated directly in the antibody backbone. In this chapter, we describe the commonly used methods for radiolabeling and characterizing the antibodies most commonly used radiohalogens (125I/131I) and radiometals (177Lu/99mTc).

Key words

Antibodies Radiometals Radioiodine Radiolabeling Tracers Iodogen Chelator DOTA DTPA 177Lu 99mTc 

References

  1. 1.
    Milenic DE, Brady ED, Brechbiel MW (2004) Antibody-targeted radiation cancer therapy. Nat Rev Drug Discov 3:488–499CrossRefGoogle Scholar
  2. 2.
    O’Donoghue JA, Bardies M, Wheldon TE (1995) Relationships between tumor size and curability for uniformly targeted therapy with beta-emitting radionuclides. J Nucl Med 36:1902–1909Google Scholar
  3. 3.
    Makrigiorgos G, Adelstein SJ, Kassis AI (1990) Auger electron emitters: insights gained from in vitro experiments. Radiat Environ Biophys 29:75–91CrossRefGoogle Scholar
  4. 4.
    Chauhan SC, Jain M, Moore ED, Wittel UA, Li J, Gwilt PR, Colcher D, Batra SK (2005) Pharmacokinetics and biodistribution of 177Lu-labeled multivalent single-chain Fv construct of the pancarcinoma monoclonal antibody CC49. Eur J Nucl Med Mol Imaging 32:264–273CrossRefGoogle Scholar
  5. 5.
    Batra SK, Jain M, Wittel UA, Chauhan SC, Colcher D (2002) Pharmacokinetics and biodistribution of genetically engineered antibodies. Curr Opin Biotechnol 13:603–608CrossRefGoogle Scholar
  6. 6.
    Jain M, Kamal N, Batra SK (2007) Engineering antibodies for clinical applications. Trends Biotechnol 25:307–316CrossRefGoogle Scholar
  7. 7.
    Anderson WT, Strand M (1987) Radiolabeled antibody: iodine versus radiometal chelates. NCI Monogr 3:149–151Google Scholar
  8. 8.
    Colcher D, Zalutsky M, Kaplan W, Kufe D, Austin F, Schlom J (1983) Radiolocalization of human mammary tumors in athymic mice by a monoclonal antibody. Cancer Res 43:736–742Google Scholar
  9. 9.
    Abrams MJ, Juweid M, TenKate CI, Schwartz DA, Hauser MM, Gaul FE, Fuccello AJ, Rubin RH, Strauss HW, Fischman AJ (1990) Technetium-99m-human polyclonal IgG radiolabeled via the hydrazino nicotinamide derivative for imaging focal sites of infection in rats. J Nucl Med 31:2022–2028Google Scholar
  10. 10.
    Goel A, Baranowska-Kortylewicz J, Hinrichs SH, Wisecarver J, Pavlinkova G, Augustine S, Colcher D, Booth BJ, Batra SK (2001) 99mTc-labeled divalent and tetravalent CC49 single-chain Fv’s: novel imaging agents for rapid in vivo localization of human colon carcinoma. J Nucl Med 42:1519–1527Google Scholar
  11. 11.
    Laemmli UK (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227:680–685CrossRefGoogle Scholar
  12. 12.
    Hens M, Vaidyanathan G, Welsh P, Zalutsky MR (2009) Labeling internalizing anti-epidermal growth factor receptor variant III monoclonal antibody with (177)Lu: in vitro comparison of acyclic and macrocyclic ligands. Nucl Med Biol 36:117–128CrossRefGoogle Scholar
  13. 13.
    Hens M, Vaidyanathan G, Zhao XG, Bigner DD, Zalutsky MR (2010) Anti-EGFRvIII monoclonal antibody armed with 177Lu: in vivo comparison of macrocyclic and acyclic ligands. Nucl Med Biol 37:741–750CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, New York 2014

Authors and Affiliations

  • Suprit Gupta
    • 1
  • Surinder Batra
    • 1
    • 2
    • 3
  • Maneesh Jain
    • 1
  1. 1.Department of Biochemistry and Molecular Biology, College of MedicineUniversity of Nebraska Medical CenterOmahaUSA
  2. 2.Eppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical CenterOmahaUSA
  3. 3.Buffet Cancer CenterOmahaUSA

Personalised recommendations